The study of JS005 injection in patients with moderate to severe psoriasis
The research company Shanghai Junshi Bioscience Co., Ltd is conducting the clinical trial Safety, Tolerance, Efficacy and Pharmacokinetics of JS005 Multiple Dosing.
JS005-002 is a randomized, double-blinded, placebo-controlled phase Ib/II clinical study to evaluate the safety, tolerability, efficacy and pharmacokinetic profiles of multiple doses of JS005 (recombinant humanized anti-IL-17A monoclonal antibody) Injection in patients with moderate to severe psoriasis.
It is planned to include 166 participants.
Actual study start date is January 14, 2021. The researchers expect to complete the study by September 30, 2023.
One primary outcome measure is the numbers of adverse event(AE), Safety evaluation will be documented as numbers of adverse event(AE).
Further details can be found here:https://ichgcp.net/clinical-trials-registry/NCT05344248
